Page 209 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

R-CHOP with lenalidomide in MYC+ LBCL
100 75 50 25
Overall survival Rearrangement [single, double, triple hit]
single hit double hit triple hit
ND 21 2 38 11
9 5
triple hit
single hit
double hit
Cumulative percentage
00 6 12 At risk:
single hit 21 21 20 double hit 38 􏰀6 􏰀0 triple hit 9 9 6
26 Jun 2019
18 months 24
15 9 22 15 4 3
Figure S2A
Cumulative percentage
100 75 50 25
Overall survival
Rearrangement [single hit, BCL2+, BCL6+, triple-hit]
single hit BCL2+ BCL6+ triple hit
ND 21 2 26 5 12 6
9 5
single hit
BCL2+
triple hit
BCL6+
00 6 At risk:
single hit 21 21 BCL2+ 26 25 BCL6+12 11 triple hit 9 9
26 Jun 2019
12
18 months 24
15 9 20
24
20 13 6 2 2 6 4 3
Figure S2B
Figure S2. Overall survival according to rearrangement status (SH vs DH vs TH).
Figure S2A: Overall survival of MYC+ LBCL patients according rearrangement status SH vs DH vs TH revealed no significant differences. Figure S2B: Overall survival of MYC+ LBCL patients according rearrangement status SH vs DH MYC/BCL2 vs DH MYC/BCL6 vs TH revealed no significant differences. Eight patients with unknown BCL2 and BCL6 rearrangement were not included in this analysis.
207
7